ReviewChemical reviews2026
Beyond the Sequence: Chemical and Topological Design and Innovations in mRNA Therapeutics.
Review in Chemical reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- N7-Methylguanosine Modification in Colorectal Cancer: Molecular Insights and Clinical Implications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Messenger RNA (mRNA) has rapidly emerged as a transformative therapeutic modality, exemplified by its growing applications in infectious diseases, oncology, and genetic disorders. The chemical programmability of mRNA allows researchers to modulate its function by introducing synthetic modifications across the molecule─from the cap structure, untranslated regions (UTRs), coding sequence (CDS) to poly(A) tail and from base, backbone to ribose sugars. Beyond sequence-level design, recent advances have introduced a new dimension of control: topological engineering. Circular RNAs, branched structures, and synthetic lariat architectures are reshaping how we approach RNA stability, immunogenicity, and translation. This review surveys recent advances in the chemical and topological engineering of mRNA, emphasizing four key areas: (1) enzymatic, chemical, and hybrid methodologies that expand the repertoire of accessible mRNA modifications; (2) synthesis strategies for linear, circular, and branched mRNA topologies; (3) structure-activity relationships governing translation efficiency, decay, and immune activation; and (4) implications for next-generation mRNA-based therapeutics. By integrating chemical synthesis, synthetic biology, and RNA structural design, researchers are beginning to unlock the full therapeutic potential of engineered mRNA molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.